department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Relay Therapeutics, Inc. ($RLAY) · pharmadog

PUBLIC COMPANY

$RLAYRelay Therapeutics, Inc.

Cambridge, MA, USupdated 3h ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

0

phase 3

1

catalysts ytd

1

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 3

Human Epidermal Growth Factor Receptor 2 Negative Breast…

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1)

view all catalysts →

🐶 Hiring Signal

8 open roles at Relay Therapeutics, Inc. →

Where Relay Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 1 Rare Disease 1

departmentProject & Program Management 2 Regulatory 2 Clinical 1 Finance 1 Legal & Compliance 1 R&D / Discovery 1

News

no news has mentioned this company yet

identifiers

ticker

$RLAY

SEC CIK

0001812364

country

US

source

sec_tickers

top tags

Cardiology1 Oncology1

mentioned in

0news items

entity-linker matched

Relay Therapeutics, Inc. earnings

Relay Therapeutics, Inc.

$RLAY18.74+0.48%

Active trials

phase2A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)recruitingn=277
phase3Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancerrecruitingn=540
phase1First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancerrecruitingn=930
phase1First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumorscompletedn=41

Data sources

last refreshed 47m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Insider activity

source: SEC Form 4

90d open-market buys

$0

0 transactions

90d open-market sells

$27K

1 transaction

net (buys − sells)

−$27K

non-derivative only

open-market buys + sells

Apr 9, 26SELLCatinazzo Thomas· Chief Financial Officer1,800 sh @ $15.00−$27K↗
Apr 7, 26SELLCatinazzo Thomas· Chief Financial Officer17,717 sh @ $13.01−$230K↗
Mar 9, 26SELLCatinazzo Thomas· Chief Financial Officer17,717 sh @ $10.06−$178K↗
Jan 28, 26SELLBergstrom Donald A· President, R&D2,686 sh @ $8.45−$23K↗
Jan 28, 26SELLCatinazzo Thomas· Chief Financial Officer1,695 sh @ $8.45−$14K↗
Jan 28, 26SELLRahmer Peter· See remarks1,354 sh @ $8.45−$11K↗
Jan 27, 26SELLBergstrom Donald A· President, R&D18,895 sh @ $7.62−$144K↗
Jan 27, 26SELLCatinazzo Thomas· Chief Financial Officer13,820 sh @ $7.62−$105K↗
Jan 27, 26SELLRahmer Peter· See remarks11,684 sh @ $7.62−$89K↗

routine RSU / option mechanics (2)

Apr 9, 26option exerciseCatinazzo Thomas · Chief Financial Officer1,800 sh
Apr 9, 26option exerciseCatinazzo Thomas · Chief Financial Officer1,800 sh

$RLAY18.74+0.48%